Stock exchanges & markets

Overview Watchlists

Sandoz H1 FY26 core diluted EPS rises 17% to USD 1.71; net sales climb 15% to USD 5.8 billion

5. Aug 2026

(AWP Alliance News) - Sandoz reported H1 2026 net sales rose 15% to USD 5.8 billion. Core EBITDA margin widened 0.9 percentage point to 20.9%, while core diluted EPS climbed 17% to USD 1.71. Management free cash flow was unchanged at USD 503 million.

The biosimilars pipeline expanded to 36 assets, with expected H2 2026 biosimilar launches including Enzeevu (aflibercept) and Ranluspec (ranibizumab), while full-year 2026 guidance was confirmed for mid-to high-single-digit net-sales growth and a roughly 100-basis-point core-EBITDA margin increase.

https://docs.publicnow.com/F863912FFC12F1A20309C87D8E0F3DA0B27BE35A

Disclaimer: This news brief was created using generative artificial intelligence. Sandoz Group AG published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • ETF Compass

    Stock exchanges & markets

    ETFs are becoming increasingly popular. Our ETF Compass helps you maintain an overview. Filter by criteria such as asset class, region, rating, return or costs. 

    Try the ETF Compass now

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now